Clinical Study to Evaluate the Possible Efficacy of Nifuroxazide in Patient With Ulcerative Colitis

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 20, 2023

Primary Completion Date

February 20, 2025

Study Completion Date

February 20, 2025

Conditions
Inflammatory Bowel Diseases
Interventions
DRUG

Mesalamine

Mesalamine, also known as 5-aminosalicylic acid (5-ASA), is a medication used to treat ulcerative colitis. It is usually used to induce or maintain remission of mildly to moderately active ulcerative colitis.

DRUG

Nifuroxazide

Nifuroxazide is an oral antibiotic that has been approved as an effective antidiarrheal agent with no side effects in several gastrointestinal infections

Trial Locations (1)

Unknown

Tanta University, Tanta

All Listed Sponsors
lead

Mostafa Bahaa

OTHER